Caris aims to bridge gap between patients, precision trials with Pharmatech takeout

Caris' acquisition of Pharmatech, announced Wednesday, will allow the molecular profiling company to offer patients, physicians and drug developers an integrated approach to identifying and enrolling patients with rare mutations and other biomarkers in precision cancer trials.